Active, not recruitingPhase 3NCT02446600
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Studying Primary peritoneal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Joyce F LiuNRG Oncology
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 579 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2016 – 2026
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
- Alaska Women's Cancer Care, Anchorage, Alaska, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Arizona Oncology Associates-West Orange Grove, Tucson, Arizona, United States
- Arizona Oncology Associates-Wilmot, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- PCR Oncology, Arroyo Grande, California, United States
- Mercy San Juan Medical Center, Carmichael, California, United States
- Marin Cancer Care Inc, Greenbrae, California, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
AstraZeneca · NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02446600 on ClinicalTrials.govOther trials for Primary peritoneal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07480954Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerTORL Biotherapeutics, LLC
- RECRUITINGPHASE3NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerImunon
- RECRUITINGPHASE2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerThe University of Hong Kong
- RECRUITINGPHASE2NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT TrialMayo Clinic
- RECRUITINGPHASE1NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersEmory University
- RECRUITINGPHASE2NCT06434610A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Shanghai Jiaolian Drug Research and Development Co., Ltd